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OBJECTIVES: Long-term continuous use of HMG-CoA
inhibitors (statins) has been shown to be beneﬁcial to
patients with coronary artery disease in several large clin-
ical trials. This study demonstrates a promising model 
to assess the relationship between medication adherence
with statins and the risk of adverse event (hospitalization
or emergency visit) in a managed care population.
METHODS: Conventional outcomes assessments for
medication compliance often encounter the problem of
identifying the causal relationship between adherence and
outcomes (e.g., adverse event). It is not unusual that med-
ication discontinuation occurs after and possibly due to
a hospitalization event. To determine the strength of the
relationship between statin adherence and risk of hospi-
talization, a Cox proportional hazard model was devel-
oped with the time-varying variable deﬁned as proportion
of days covered by statins (PDC) as of the date of ﬁrst
adverse event. For censored subjects, PDC was chosen as
of the end of study period or the date of disenrollment,
whichever occurred ﬁrst. 68,974 adult patients were 
identiﬁed as new statin starters during a 2-year period
from June 1998 to June 2000. Other covariates included
demographics, payer types, previous drug, medical and
procedure uses, and comorbidities. RESULTS: The time
varying covariate (PDC) was the second most signiﬁcant
predictor of time to adverse event (chi-square < 1610.9,
p < 0.0001). The most signiﬁcant predictor of an adverse
event was the existence of a previous adverse event (chi-
square = 2043.1, p < 0.0001). Patients with higher age,
comorbidities and previous high utilization have higher
risk. In addition, patients in HMO and POS have signiﬁ-
cant lower risk than patients with FFS and PPO. CON-
CLUSIONS: Time-varying PDC is one of the strongest
predictors of the risk of an adverse event. Persistence is
signiﬁcantly associated with lower risk of occurrence of
hospitalization or emergency visit.
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RELATIONSHIP BETWEEN DIRECT-TO-
CONSUMER ADVERTISING AND PRODUCT
INNOVATIVENESS
Fuldeore M, Krueger K
Auburn University, Auburn, AL, USA
OBJECTIVE: The purpose of this study is to determine
if there is a relationship between product innovativeness
and direct-to-consumer advertisement. METHODS:
Products advertised directly to the consumer (DTC) were
divided into two categories using the FDA therapeutic
and chemical classiﬁcation system. New molecular enti-
ties and products with priority reviews were classiﬁed as
‘innovative’; all other standard review products were clas-
siﬁed as ‘standard’. Information on product classiﬁcation
and the total number of products approvals was obtained
from FDA prescription drug approval data. The amount
spent on DTC advertising between 1997 and 2001 was
obtained from published data. Products with less than a
0.1% share of annual DTC expenditures were excluded,
as were products launched before 1990, and vaccines 
and biotech products. The average annual expenditure on
DTC advertisement from 1997–2001 was calculated for
each product. Data were analyzed using chi-square and
t-tests. RESULTS: The inclusion criteria were met by 106
distinct products. The proportion of products advertised
in the innovative group was signiﬁcantly higher than the
standard group (p < 0.006). Innovative products are 1.7
times more likely to be advertised directly to the con-
sumer than the standard products. There was no statisti-
cal difference in the average annual DTC expenditure per
product in each group (p = 0.63). CONCLUSION: Inno-
vative products are more likely to be advertised directly
to the consumer which may increase patients’ request for
those medications. This information may help decision
makers understand potential product demand during the
formulary decision making process.
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OBJECTIVE: The purpose of this study was to describe
the economic impact of generic ﬂuoxetine entry on trends
in utilization and costs of new generation antidepressants
(Celexa®, Effexor®, Luvox®, Paxil®, Prozac®, and
Zoloft®) within the Texas Medicaid Program. Addition-
ally, diffusion of market share among generic manufac-
turers following the 180-day marketing exclusivity period
was also examined. METHODS: Retrospective prescrip-
tion claims data from January 2001 through August 2002
were analyzed. Claims were grouped across study agents:
1) Prozac®, 2) ﬂuoxetine, and 3) other (Celexa®,
Effexor®, Luvox®, Paxil®, and Zoloft®) antidepres-
sants. Costs were based on payments to pharmacies.
RESULTS: A total of 1,154,565 prescription claims were
analyzed. Prior to the introduction of generic ﬂuoxetine,
market share for Prozac® was 19.0% (10,754 claims) in
July 2001. In August 2002, market share for Prozac®
decreased to 2.2% (1,479 claims), of which, 952 claims
(64.3%) were for the Prozac® 20mg weekly dose, while
market share for “other antidepressants” grew to 86.7%
(57,259 claims). Generic ﬂuoxetine market share was
11.0% (7,281 claims) in August 2002. Within the generic
ﬂuoxetine market, manufacturers with exclusivity experi-
enced a decrease in market share from 100.0% (7,184
claims) in January 2002 to 63.6% (4,629 claims) in
August 2002. The estimated average payment per unit
(post-rebate) for Prozac® 20mg capsules prior to its
patent expiration (January–July 2001), during the 180-
day generic exclusivity period (August 2001–January
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2002), and after the exclusivity period (February–August
2002) was: $1.89, $1.91, and $1.97 respectively, using an
assumed percentage rebate. Similarly, average estimated
payment per unit (post-rebate) for ﬂuoxetine 20mg 
capsules (generic) in the 2 latter periods was: $1.96 and
$0.79 respectively. Additional payments related to 
cost-savings not realized were estimated to be
$1,772,677. CONCLUSIONS: Regulations that limit
competition within the generic marketplace immediately
following branded patent-expiration may result in lost
opportunities for savings within publicly-ﬁnanced pre-
scription programs.
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OBJECTIVES: The overall purpose of this study was 
to determine West Virginia (WV) physicians’ attitude
toward cost-containment strategies and generic prescrib-
ing, and to assess their level of awareness and receptivity
towards academic detailing. METHODS: The top 2000
physicians by prescribing volume in the WV state employ-
ees health insurance program were surveyed using a 
self-administered mail questionnaire. Physician attitudes
toward popular pharmaceutical cost-control strategies
(formulary, prior-authorization, co-pays, generic and
therapeutic substitution, and incentives for formulary
adherence), generic prescribing, and the potential of 
academic detailing for appropriate and cost-effective
pharmaceutical use was assessed using Likert-type 
7-point scales. Generic prescribing frequency and patient
acceptance/inquiry for generic drugs and the preferred
format of academic detailing visits were also obtained.
RESULTS: A total of 455 (23%) usable responses were
obtained after 2 mailings. On a scale of 1 to 7 (highly
inappropriate to highly appropriate), generic substitu-
tion, increased patient co-pays for branded drugs, and
therapeutic substitution had the highest mean appro-
priateness scores of 5.30 (+1.68), 4.49 (+1.71), and
4.36(+2.01), respectively. All other strategies were 
considered inappropriate with incentives to physicians 
for prescribing from formularies considered the most
inappropriate. Physicians were neutral to mildly positive
toward generic drug prescribing, and reported a mean
proportion of 46% generic prescriptions written and a
78% patient acceptance of generic prescriptions when
written. Physicians were generally aware of academic
detailing and mildly positive about it with 69% of 
surveyed physicians expressing willingness to meet with
academic detailers. A once-a-month frequency of visit and
up to 20 minutes per visit was favored by almost half of
those physicians interested in academic detailing. CON-
CLUSIONS: Overall, WV physicians are less supportive
of cost-control strategies that impose restrictions on their
prescribing and more supportive of strategies that do not
impose on their prescribing. Study results indicate that
WV physicians are receptive to academic detailing.
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ARE SICK PEOPLE LESS RESPONSIVE TO
PRESCRIPTION BENEFIT CHANGES?
Xiao Q, Marks AS, Patel H
Caremark Inc, Northbrook, IL, USA
OBJECTIVES: To estimate the difference in respon-
siveness to drug beneﬁt changes between sick and 
healthy populations under different drug beneﬁt plans.
METHODS: Prescription spending in 2001, demo-
graphic, co-pays and chronic condition information of
107,710 primary participants between ages 18 to 64 was
obtained from Caremark PBM claims system. Existence
of chronic conditions identiﬁed through pharmacy claims
utilization algorithms was used as a proxy for sick people.
A 2-part model was used to estimate the prescription
spending on copay changes. The ﬁrst part used a logistic
regression to estimate the probability of incurring of any
prescription. The second part used an OLS regression 
on log of total spending for the utilizing participants.
RESULTS: Under a 1-Tier copay plan, if the co-pays
increase from $5 to $10, the reduction of total spending
is 6.4% more for sick people than for healthy people.
Under a 2-Tier plan, if the co-pays increase from $5 to
$10 for generic and $10 to $15 for brand, the reduction
of total spending is 10.2% more for sick people than 
for healthy people. Under a 3-Tier plan, if the co-pays
increase from $5 to $10 for generic, $10 to $15 for brand
formulary and $15 to $20 for brand non-formulary, the
reduction of total spending is 10.4% more for sick people
than for healthy people. CONCLUSIONS: Based on the
speciﬁc data set, this research shows that sick people 
are more responsive to drug beneﬁt changes. Since cost-
sharing designs are frequently used to contain total drug
spending, understanding drug beneﬁt designs for hetero-
geneous populations is crucial to achieve the optimal
balance of sponsor savings and participants’ health.
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IMPACT OF PARTICIPANT COST-SHARE ON
COMPLIANCE RATES IN PARTICIPANTS WITH
DIABETES
Moore JM, Marks AS, Kassulke JP, Patel H
Caremark, Inc, Northbrook, IL, USA
OBJECTIVE: To retrospectively assess the impact of par-
ticipant cost-share levels on medication compliance rates
